-+ 0.00%
-+ 0.00%
-+ 0.00%

Camp4 Therapeutics CEO Josh Mandel-Brehm acquires 6,551 common shares for $10,809.15

PUBT·08/05/2026 21:14:40
Listen to the news
Camp4 Therapeutics CEO Josh Mandel-Brehm acquires 6,551 common shares for $10,809.15
  • Camp4 Therapeutics CEO Josh Mandel-Brehm bought 6,551 common shares at USD 1.65 each.
  • His direct holding rose to 284,968 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053505), on August 05, 2026, and is solely responsible for the information contained therein.